Impact of genetic alteration on mTOR-targeted cancer therapy

Chinese Journal of Cancer

Volumn 32, Issue 5, 2013, Pages 270-274

  Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; mTOR; Mutation; Rapalogs

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BEVACIZUMAB; DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; RAPAMYCIN; S6 KINASE; S6 KINASE 2; TEMSIROLIMUS; TUBERIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; KRAS PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; PTEN PROTEIN, HUMAN; RAS PROTEIN; STK11 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER INHIBITION; CANCER REGRESSION; CLINICAL STUDY; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; LKB1 GENE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PI3K GENE; PI3KCA GENE; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TSC GENE; TSC1 GENE; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; GENETICS; METABOLISM; MUTATION; NEOPLASM; TUMOR CELL LINE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; NEOPLASMS;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; HUMANS; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84877266764     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10005     Document Type: Review

References (38)

1. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev, 2004,18:1926-1945.
2. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer, 2004,4:335-348.
3. Shaw RJ, Cantley LC. Ras, PI (3)K and mTOR signaling controls tumour cell growth. Nature, 2006,441:424-430.
4. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell, 2007,12:9-22.
5. Bhagwat SV, Crew AP. Novel inhibitors of mTORC1 and mTORC2. Curr Opin Investig Drugs, 2010,11:638-645.
6. Garcia Echeverria C. Allosteric and ATP competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett, 2010,20:4308-4312.
7. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med, 2007,356:2271-2281.
8. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 2009,115:2438-2446.
9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo controlled phase III trial. Lancet, 2008,372:449-456.
10. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011,364: 514-523.
11. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat, 2008,11:32-50.
12. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med, 2007,13:433-442.
13. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res, 2007,13:3109-3114.
14. Gandhi L, Janne PA. Crizotinib for ALK re arranged non -small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res, 2012,18:3737-3742.
15. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci, 2009,122:3589-3594.
16. Ma L, Chen Z, Erdjument Bromage H, et al. Phosphory la tion and functional inactivation of TSC2 by ERK implications for tuberous sclerosis and cancer pathogenesis. Cell, 2005,121: 179-193.
17. Carriere A, Cargnello M, Julien LA, et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol, 2008, 18:1269-1277.
18. Wang X, Sun SY. Enhancing mTOR ta rgeted cancer therapy. Expert Opin Ther Targets, 2009,13:1193-1203.
19. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell, 2008,134: 451-460.
20. Feng Z, Zhang H, Levine AJ, et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A, 2005,102:8204-8209.
21. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle, 2011,10:2305-2316.
22. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A, 2001,98:10314-10319.
23. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI 779. Cancer Res, 2002,62:5027-5034.
24. Steelman LS, Navolanic PM, Sokolosky ML, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene, 2008,27:4086-4095.
25. Paradiso A, Mangia A, Azzariti A, et al. Phosphatidylinositol 3-kinase in breast cancer: where from here? Clin Cancer Res, 2007,13:5988-5990.
26. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011,30: 3222-3233.
27. Meric Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res, 2012,18:1777-1789.
28. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest, 2010,120:2858-2866.
29. Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer, 2009,100:370-375.
30. Contreras CM, Akbay EA, Gallardo TD, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech, 2010,3:181-193.
31. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science, 2012, 338: 221.
32. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant cell astrocytomas in tuberous sclerosis. N Engl J Med, 2010,363:1801-1811.
33. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST 1): a multicentre, randomised, placebo controlled phase 3 trial. Lancet, 2013,381:125-132.
34. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol, 2012,30:777-782.
35. Pao W, Girard N. New driver mutations in non-small cell lung cancer. Lancet Oncol, 2011,12:175-180.
36. Sanders HR, Albitar M. Somatic mutations of signaling genes in non-small cell lung cancer. Cancer Genet Cytogenet, 2010, 203:7-15.
37. Sanchez Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz J eghers syndrome. Oncogene, 2007,26: 7825-7832.
38. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone re captor-positive advanced breast cancer. N Engl J Med, 2012,366:520-529.